Raymond James analyst Danielle Brill downgraded FibroGen to Market Perform from Outperform with no price target after the company’s Phase 3 ZEPHYRUS-1 study did not meet the primary endpoint.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FGEN: